This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shou, W. Articles by Matzuk, M. M. Search for Related Content PubMed PubMed Citation Articles by Shou, W. Articles by Matzuk, M. M.

Role of Androgens in Testicular Tumor Development in Inhibin-Deficient Mice¹

Departments of Pathology (W.S., M.M.M.), Cell Biology (M.M.M.), and Molecular and Human Genetics (M.M.M.), Baylor College of Medicine, Houston, Texas 77030; and the Departments of Medicine, and Neurobiology and Physiology, Northwestern University (T.K.W.), Chicago, Illinois 60611

Address all correspondence and requests for reprints to: Dr. Martin M. Matzuk, Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030. E-mail: mmatzuk{at}bcm.tmc.edu

To understand gonadal tumor development, we have previously created a mouse model in which mice deficient in the inhibins develop gonadal sex cord-stromal tumors with essentially 100% penetrance. These tumors develop as early as 4 weeks of age and cause cancer cachexia-like symptoms and subsequent death in the inhibin-deficient mice. Gonadectomized inhibin-deficient mice eventually develop adrenal cortical tumors with nearly 100% penetrance. These studies have identified inhibin as a novel secreted tumor suppressor protein with specificity for the gonads and adrenal glands. Sex steroids have been implicated to influence gonadal tumor development in humans and mice. To determine the role of androgens in gonadal tumorigenesis in inhibin-deficient male mice, we have used a genetic intercross strategy, breeding inhibin mutant mice with tfm (testicular feminization, a naturally occurring androgen receptor mutant) carrying females to eventually generate compound mutant male mice that lack inhibins and carry the tfm mutation. These compound mutant mice, like inhibin-deficient mice, continue to develop testicular tumors and the accompanying cancer cachexia-like wasting syndrome. Consistent with these findings, elevated levels of activins A and B secreted from the gonadal tumors are seen in the adult compound mutant mice as well as the secondary pathological consequences of these high activin levels in the livers and glandular stomachs. However, in contrast to male mice lacking only inhibin, in which essentially 100% of the testicular tumors are hemorrhagic, 65% of the tumors in these compound mutant male mice are less hemorrhagic, and approximately 50% of the compound mutants live longer than 17 weeks of age (95% of the male mice lacking only inhibin die by 12 weeks). These results suggest that androgens are not required for testicular tumor development in inhibin-deficient mice, but may play a regulatory role in testicular tumor progression.

This article has been cited by other articles:

				Q. Li, J. M. Graff, A. E. O'Connor, K. L. Loveland, and M. M. Matzuk SMAD3 Regulates Gonadal Tumorigenesis Mol. Endocrinol., October 1, 2007; 21(10): 2472 - 2486. [Abstract] [Full Text] [PDF]

				Q. Li, R. Kumar, K. Underwood, A. E. O'Connor, K. L. Loveland, J. S. Seehra, and M. M. Matzuk Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein Mol. Hum. Reprod., September 1, 2007; 13(9): 675 - 683. [Abstract] [Full Text] [PDF]

				K. H. Burns, J. E. Agno, L. Chen, B. Haupt, S. C. Ogbonna, K. S. Korach, and M. M. Matzuk Sexually Dimorphic Roles of Steroid Hormone Receptor Signaling in Gonadal Tumorigenesis Mol. Endocrinol., October 1, 2003; 17(10): 2039 - 2052. [Abstract] [Full Text] [PDF]

				K. H. Burns, G. E. Owens, S. C. Ogbonna, J. H. Nilson, and M. M. Matzuk Expression Profiling Analyses of Gonadotropin Responses and Tumor Development in the Absence of Inhibins Endocrinology, October 1, 2003; 144(10): 4492 - 4507. [Abstract] [Full Text] [PDF]

				F. Beuschlein, B. D. Looyenga, S. E. Bleasdale, C. Mutch, D. L. Bavers, A. F. Parlow, J. H. Nilson, and G. D. Hammer Activin Induces x-Zone Apoptosis That Inhibits Luteinizing Hormone-Dependent Adrenocortical Tumor Formation in Inhibin-Deficient Mice Mol. Cell. Biol., June 1, 2003; 23(11): 3951 - 3964. [Abstract] [Full Text] [PDF]

				G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]

				T. R. Kumar, G. Palapattu, P. Wang, T. K. Woodruff, I. Boime, M. C. Byrne, and M. M. Matzuk Transgenic Models to Study Gonadotropin Function: The Role of Follicle-Stimulating Hormone in Gonadal Growth and Tumorigenesis Mol. Endocrinol., June 1, 1999; 13(6): 851 - 865. [Abstract] [Full Text]

				Rilianawati, T. Paukku, J. Kero, F.-P. Zhang, N. Rahman, K. Kananen, and I. Huhtaniemi Direct Luteinizing Hormone Action Triggers Adrenocortical Tumorigenesis in Castrated Mice Transgenic for The Murine Inhibin {alpha}-Subunit Promoter/Simian Virus 40 T-Antigen Fusion Gene Mol. Endocrinol., June 1, 1998; 12(6): 801 - 809. [Abstract] [Full Text]